Yes. The standard regimen is one drop in each affected eye once daily. Using the medication in both eyes ensures uniform intra-ocular pressure reduction.
A mild burning sensation is common and usually resolves within a few minutes. If discomfort continues beyond 15 minutes or worsens, contact an eye-care professional to rule out irritation or allergy.
Combigan can be used alongside prostaglandin analogues or carbon-ic anhydrase inhibitors if monotherapy does not achieve target IOP. Your ophthalmologist will determine the safest combination and monitor for additive side effects.
Combigan bottles feature a preservative-free, single-use dropper tip that limits contamination. However, the solution should still be stored as directed and discarded after 30 days of opening.
Caffeine does not directly interfere with the pharmacology of brimonidine or timolol. Nonetheless, excessive caffeine can raise blood pressure, which may indirectly influence ocular perfusion.
It is advisable to wait at least 15 minutes after drop administration before inserting contact lenses to ensure the medication is fully absorbed and to avoid lens contamination.
Although applied locally, a small amount of brimonidine and timolol can enter systemic circulation, potentially causing bradycardia, hypotension, or bronchospasm in susceptible individuals.
Some patients report transient blurred vision or difficulty focusing after dosing, especially if the drop contacts the cornea. This effect typically resolves quickly and does not impair night vision long-term.
Because β-blockers can cause fatigue or visual changes, individuals who operate aircraft or heavy machinery should ensure Combigan does not affect their alertness or visual acuity before performing safety-critical tasks.
Clinical studies have shown that the combination provides greater IOP reduction than either agent taken separately, reducing the need for multiple bottles and simplifying the dosing schedule.
Combigan is an ophthalmic solution that contains two active ingredients - brimonidine tartrate (0.2%) and timolol maleate (0.5%). It belongs to the eye-care therapeutic class and is indicated for lowering intra-ocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension. The product is supplied in a sterile bottle for topical eye-drop administration and is prescription-only (Rx) in the United Kingdom, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Combigan combines two complementary mechanisms to reduce IOP:
Brimonidine tartrate is an α2-adrenergic agonist. By activating α2 receptors in the ciliary body, it decreases aqueous-humour production and increases uveoscleral outflow, leading to a modest IOP reduction.
Timolol maleate is a non-selective β-blocker. It blocks β-adrenergic receptors in the ciliary epithelium, further reducing aqueous-humour formation.
Together, the agents provide an additive effect, achieving a greater and more consistent IOP-lowering response than either component alone. The onset of action is typically within 30 minutes, with peak effect around 6-8 hours, and the duration can extend up to 24 hours, supporting once-daily dosing.
Combigan is approved in the UK for:
These indications are supported by data submitted to the MHRA and reflected in NICE guidance for glaucoma management. The medication is intended for adult patients where monotherapy with either brimonidine or timolol does not achieve target IOP.
Absolute contraindications
Relative contraindications
Special populations such as the elderly may be more sensitive to systemic β-blockade and should be monitored for bradycardia or fatigue.
If any of these serious signs develop, patients should seek immediate medical attention.
Patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, and herbal supplements.
Regular follow-up ensures the target IOP is achieved without adverse effects.
This article provides educational information about Combigan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
